{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:00:49Z","timestamp":1787032849327,"version":"build-2736575974"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,5]]},"DOI":"10.7759\/cureus.100833","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:02:39Z","timestamp":1767625359000},"source":"Crossref","is-referenced-by-count":1,"title":["Circulating Tumor DNA in Breast Cancer: Diagnostic Insights From a Case Series"],"prefix":"10.7759","author":[{"given":"Cortney","family":"McKay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasnim","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin","family":"Ghimire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual J","year":"2022","unstructured":"Pascual J, Attard G, Bidard FC, et al.. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group. Ann Oncol. 2022, 33:750-68. 10.1016\/j.annonc.2022.05.520","journal-title":"Ann Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2022-251196","article-title":"Use of circulating tumour DNA in nasopharyngeal carcinoma to detect minimal residual disease","volume":"15","author":"Ghimire B","year":"2022","unstructured":"Ghimire B, Herrman E, Karki U, Chisti MM. Use of circulating tumour DNA in nasopharyngeal carcinoma to detect minimal residual disease. BMJ Case Rep. 2022, 15:e251196. 10.1136\/bcr-2022-251196","journal-title":"BMJ Case Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00876-y","article-title":"Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology","volume":"9","author":"Bartolomucci A","year":"2025","unstructured":"Bartolomucci A, Nobrega M, Ferrier T, et al.. Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology. NPJ Precis Oncol. 2025, 9:84. 10.1038\/s41698-025-00876-y","journal-title":"NPJ Precis Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102390","article-title":"Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: A systematic review and meta-analysis","volume":"9","author":"Nader-Marta G","year":"2024","unstructured":"Nader-Marta G, Monteforte M, Agostinetto E, et al.. Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: A systematic review and meta-analysis. ESMO Open. 2024, 9:102390. 10.1016\/j.esmoop.2024.102390","journal-title":"ESMO Open"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3014","article-title":"A multigene assay determines risk of recurrence in patients with triple\u2011negative breast cancer","volume":"79","author":"Stewart RL","year":"2019","unstructured":"Stewart RL, Updike KL, Factor RE, Henry NL, Boucher KM, Bernard PS, Varley KE. A multigene assay determines risk of recurrence in patients with triple\u2011negative breast cancer. Cancer Res. 2019, 79:3466-78. 10.1158\/0008-5472.CAN-18-3014","journal-title":"Cancer Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00091-1","article-title":"Switching endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer with ESR1 mutation detected by circulating tumor DNA analysis (SERENA-6): a phase 3, randomised, open-label trial","volume":"3","author":"Bidard F-C","year":"2025","unstructured":"Bidard F-C, Fribbens C, Robertson JFR, et al.. Switching endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer with ESR1 mutation detected by circulating tumor DNA analysis (SERENA-6): a phase 3, randomised, open-label trial. Lancet Oncol. 2025, 3:529-42. 10.1016\/S1470-2045(25)00091-1","journal-title":"Lancet Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie J","year":"2022","unstructured":"Tie J, Cohen JD, Lahouel K, et al.. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022, 386:2261-72. 10.1056\/NEJMoa2200075","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer current: Status, challenges and future prospects","volume":"9","author":"Ma L","year":"2024","unstructured":"Ma L, Guo H, Zhao Y, et al.. Liquid biopsy in cancer current: Status, challenges and future prospects. Signal Transduct Target Ther. 2024, 9:336. 10.1038\/s41392-024-02021-w","journal-title":"Signal Transduct Target Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28565","article-title":"Analytical validation of NeXT Personal\u00ae, an ultra-sensitive personalized circulating tumor DNA assay","volume":"15","author":"Northcott J","year":"2024","unstructured":"Northcott J, Bartha G, Harris J, et al.. Analytical validation of NeXT Personal\u00ae, an ultra-sensitive personalized circulating tumor DNA assay. Oncotarget. 2024, 15:200-18. 10.18632\/oncotarget.28565","journal-title":"Oncotarget"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140712","article-title":"Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell\u2011free circulating tumor DNA","volume":"10","author":"Lanman RB","year":"2015","unstructured":"Lanman RB, Mortimer SA, Zill OA, et al.. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell\u2011free circulating tumor DNA. PLoS One. 2015, 10:e0140712. 10.1371\/journal.pone.0140712","journal-title":"PLoS One"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/445744-circulating-tumor-dna-in-breast-cancer-diagnostic-insights-from-a-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:02:40Z","timestamp":1767625360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/445744-circulating-tumor-dna-in-breast-cancer-diagnostic-insights-from-a-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.100833","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,5]]}}}